Shire To Begin Promoting Adderall XR Adult Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Adults represent 15%-20% of Adderall XR total scripts, Shire says. The company will be required to submit additional clinical data to receive approval for doses above 30 mg.
You may also be interested in...
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
Company plans a "Dear Doctor" letter informing U.S. physicians of Health Canada's decision. FDA says it "has not decided to take any further regulatory action at this time"; sudden death warnings were added to Adderall XR's labeling in August.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: